Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Brokerages

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned a consensus rating of "Buy" from the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $21.29.

A number of equities research analysts recently commented on STOK shares. Cantor Fitzgerald restated an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. HC Wainwright restated a "buy" rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Leerink Partners assumed coverage on shares of Stoke Therapeutics in a report on Monday, October 14th. They issued an "outperform" rating and a $18.00 target price for the company. Chardan Capital assumed coverage on shares of Stoke Therapeutics in a report on Friday, December 20th. They issued a "buy" rating and a $24.00 target price for the company. Finally, Leerink Partnrs raised shares of Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th.

Stoke Therapeutics Trading Up 0.3 %

Shares of STOK traded up $0.04 during mid-day trading on Friday, hitting $11.52. 1,010,191 shares of the company's stock were exchanged, compared to its average volume of 843,438. Stoke Therapeutics has a fifty-two week low of $4.09 and a fifty-two week high of $17.58. The firm has a market capitalization of $610.21 million, a P/E ratio of -5.49 and a beta of 0.95. The business's 50 day moving average is $11.07 and its two-hundred day moving average is $12.66.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts forecast that Stoke Therapeutics will post -2.03 earnings per share for the current year.

Insiders Place Their Bets

In other Stoke Therapeutics news, CEO Edward M. Md Kaye sold 6,786 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $12.99, for a total value of $88,150.14. Following the completion of the sale, the chief executive officer now directly owns 61,885 shares of the company's stock, valued at approximately $803,886.15. The trade was a 9.88 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total transaction of $120,700.00. Following the completion of the sale, the insider now directly owns 51,277 shares of the company's stock, valued at $618,913.39. The trade was a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 62,849 shares of company stock valued at $809,421. Company insiders own 11.30% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Hedge funds have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. acquired a new position in shares of Stoke Therapeutics in the 4th quarter valued at $124,000. Intech Investment Management LLC acquired a new position in shares of Stoke Therapeutics in the 3rd quarter valued at $160,000. The Manufacturers Life Insurance Company boosted its holdings in shares of Stoke Therapeutics by 16.7% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock valued at $189,000 after purchasing an additional 1,994 shares during the last quarter. Mesirow Financial Investment Management Inc. acquired a new position in shares of Stoke Therapeutics during the 3rd quarter valued at $192,000. Finally, Rhumbline Advisers lifted its holdings in shares of Stoke Therapeutics by 6.0% during the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company's stock valued at $545,000 after acquiring an additional 2,787 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.